pharmaphorum2y
Olumiant benefits additive to other drugs in severe COVID patients
Eli Lilly and Incyte's JAK inhibitor Olumiant reduced the risk of death by 13% in hospitalised COVID-19 patients when added to other drugs, according to new results from the UK RECOVERY trial.
pharmaphorum3y
Lilly's Olumiant flunks COVID-19 trial – or does it?
Eli Lilly's JAK inhibitor Olumiant has missed its main objective in a phase 3 trial in hospitalised COVID-19 patients, but had a significant effect on mortality, a secondary endpoint.
Arthritis Foundation1y
FDA Approves a New Oral Drug for Moderate to Severe RA
The U.S. Food and Drug Administration (FDA) recently approved baricitinib (Olumiant), a pill that is taken once a day. Baricitinib is a targeted disease-modifying antirheumatic drug (DMARD) that ...